Back to top
more

Genomic Health, Inc. (GHDX)

(Delayed Data from NSDQ)

$67.55 USD

67.55
321,603

+1.67 (2.53%)

Updated May 3, 2019 04:00 PM ET

After-Market: $67.63 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Abiomed (ABMD) to Replace Wyndham in the S&P 500 Benchmark

Abiomed (ABMD) to join the S&P 500 Global Industry Classification Standard Health Care Supplies Sub-Industry index.

    Intuitive Surgical (ISRG) Gains on Strength in Robotics

    Higher adoption of Intuitive Surgical's (ISRG) robot-based da Vinci system and increasing procedure volumes are key catalysts at the moment.

      Allscripts' iPro Anesthesia to be Administered by SingHealth

      Allscripts (MDRX) goes global, joining hands with Singapore-based hospital to implement iPro Anesthesia.

        Here's Why You Should Buy Cooper Companies (COO) Stock Now

        Cooper Companies (COO) is set to gain from expanding product portfolio and increasing penetration in international markets.

          Ecolab (ECL) Launches SMARTPOWER for Warewashing Efficiency

          Ecolab (ECL) rolls out SMARTPOWER program for efficient ware washing and reducing labor costs for restaurateurs.

            Allscripts Acquires HealthGrid to Improve Patient Outcome

            Allscripts' (MDRX) HealthGrid buyout to drive FollowMyHealth platform.

              Ligand Pharmaceuticals (LGND) Hits a 52-Week High, Can the Run Continue?

              Ligand Pharmaceuticals Incorporated is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LGND for clues.

                Cerner-VA Pact to Use EHR Platform for Better Veteran Service

                Department of Veterans Affairs adopts Cerner's (CERN) EHR system to serve the veteran community better.

                  Varian Medical (VAR) Merges With Brazil MOH to Fight Cancer

                  Varian Medical (VAR) opts to spread radiotherapy accessibility in Latin America through Brazil MOH, other international ventures of the company hold promise.

                    Here's Why You Should Steer Clear of Cerner (CERN) for Now

                    Cerner's (CERN) downbeat view for 2018 and soft Q1 results fail to cheer investors.

                      Here's Why You Should Sell DENTSPLY SIRONA (XRAY) Stock Now

                      A rapidly changing healthcare environment in the United States, sluggish first quarter, declining margins and foreign exchange headwinds continue to hurt DENTSPLY SIRONA (XRAY).

                        Weakness Seen in Anika Therapeutics (ANIK) Estimates: Should You Stay Away?

                        Anika Therapeutics (ANIK) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.

                          Thermo Fisher (TMO) Gains on Latest Buyouts Despite Cost Woes

                          Successive product launches and a marked progress in precision medicine initiatives boost Thermo Fisher's (TMO) performance.

                            Abaxis (ABAX) to be Acquired by Zoetis, Shares All-Time High

                            Post takeover of Abaxis' (ABAX) point-of-care diagnostic instruments, Zoetis expects the consolidated company's veterinary diagnostics category to speed up growth over the animal health industry.

                              Cerner's (CERN) EHR Picked by Crisp Regional, Shares Up

                              Crisp Regional chooses to implement Cerner's (CERN) EHR platform with a view to serve the community better.

                                Veeva Systems Launches Veeva Nitro, Boosts MedTech Analytics

                                Veeva Systems' (VEEV) new commercial data warehouse establishes a solid data foundation, which will boost AI and analytics in the MedTech industry.

                                  Can The Uptrend Continue for Genomic Health (GHDX)?

                                  Investors certainly have to be happy with Genomic Health, Inc. (GHDX) and its short term performance

                                    Baxter (BAX) Gets FDA Nod for Spectrum IQ, Secures Infusions

                                    Baxter (BAX) streamlines EMR integration for patients through FDA's approval of Spectrum IQ.

                                      Here's Why You Should Sell Fresenius Medical (FMS) Stock Now

                                      A rapidly changing healthcare environment in the United States, sluggish Q1 and competition in the niche markets are major headwinds for Fresenius Medical (FMS).

                                        Here's Why You Should Invest in Varian Medical (VAR) Now

                                        Strong fundamentals and solid Q2 results make Varian Medical (VAR) a must buy.

                                          Cerner EHR Range Picked by Indiana's FSSA for Patient Care

                                          Cerner (CERN) gains as Indiana FSSA chooses its flagship Cerner Millennium solutions to take better care of patients.

                                            Here's Why You Should Invest in Intuitive Surgical Right Now

                                            Intuitive Surgical (ISRG) gains on solid Q1 results and strength in da Vinci platform.

                                              Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Low

                                              Within Genomic Health's (GHDX) prostate cancer business, strengthened NCCN prostate cancer guidelines and additional new data increase private coverage for the Oncotype DX GPS test.

                                                Why Is Genomic Health (GHDX) Up 1.6% Since Its Last Earnings Report?

                                                Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                  Genomic Health (GHDX) Q4 Earnings & Revenues Miss Estimates

                                                  Genomic Health's (GHDX) escalating operating expenses dent bottom line in Q4.